Roxane Asks Fed. Circ. To Halt Hetero's Generic Kidney Drug
By Jimmy Hoover ( October 7, 2016, 4:27 PM EDT) -- Roxane Laboratories Inc. blasted a New Jersey federal judge's ruling that a generic calcium acetate drug from Hetero Drugs Ltd. units likely doesn't infringe Roxane's kidney medication patent and should therefore be allowed on the market, explaining to a Federal Circuit panel Friday that the difference in capsule size between the two drugs is insignificant in view of the patent claims....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.